Details

Autor(en) / Beteiligte

• Ledford, Heidi

Titel

COVID antiviral pills: what scientists still want to know

Ist Teil von

• Nature (London), 2021-11, Vol.599 (7885), p.358-359

Ort / Verlag

London: Nature Publishing Group

Erscheinungsjahr

2021

Link zum Volltext

Beschreibungen/Notizen

• Researchers will be looking at the ages and ethnicities of those who were enrolled in the trials, and at any other health conditions that they had, says John Mellors, an infectious-disease specialist at the University of Pittsburgh Medical Center in Pennsylvania. Because antiviral drugs often need to be given early in the course of an infection, Mellors will also be looking for more detail about when the drugs were given in the trials, and at how those timings correlated with efficacy. Researchers should also closely monitor people who receive the drugs and have weakened immune systems. Because infections might last longer in these people, there could be more opportunity for resistance to emerge, says Richman. The situation is all too familiar, says John Amuasi, leader of the Global Health and Infectious Diseases Research Group at the Kumasi Centre for Collaborative Research in Tropical Medicine in Ghana.